CAM
EW icon

Cresset Asset Management’s Edwards Lifesciences EW Stock Holding History

Cresset Asset Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$841K Sell
9,296
-1,148
-11% -$96.2K ﹤0.01% 976
2026
Q1 		$836K Buy
10,444
+1,423
+16% +$117K ﹤0.01% 858
2025
Q4 		$769K Sell
9,021
-101
-1% -$8.29K ﹤0.01% 896
2025
Q3 		$709K Buy
9,122
+488
+6% +$38.1K ﹤0.01% 880
2025
Q2 		$675K Sell
8,634
-2,183
-20% -$163K ﹤0.01% 811
2025
Q1 		$784K Sell
10,817
-6,913
-39% -$495K ﹤0.01% 872
2024
Q4 		$1.31M Sell
17,730
-30,481
-63% -$2.13M 0.01% 696
2024
Q3 		$3.18M Buy
48,211
+1,754
+4% +$127K 0.01% 602
2024
Q2 		$4.29M Buy
46,457
+3,878
+9% +$343K 0.02% 465
2024
Q1 		$4.07M Buy
42,579
+14,948
+54% +$1.26M 0.02% 416
2023
Q4 		$2.11M Sell
27,631
-9,599
-26% -$668K 0.01% 565
2023
Q3 		$2.58M Sell
37,230
-6,702
-15% -$539K 0.01% 466
2023
Q2 		$4.14M Buy
43,932
+36,434
+486% +$3.17M 0.01% 463
2023
Q1 		$620K Sell
7,498
-2,304
-24% -$181K 0.01% 438
2022
Q4 		$270K Buy
9,802
+584
+6% +$45K ﹤0.01% 559
2022
Q3 		$762K Sell
9,218
-1,638
-15% -$158K 0.01% 411
2022
Q2 		$1M Sell
10,856
-2,473
-19% -$256K 0.01% 379
2022
Q1 		$1.57M Sell
13,329
-3,013
-18% -$338K 0.02% 298
2021
Q4 		$2.12M Buy
16,342
+1,233
+8% +$144K 0.02% 287
2021
Q3 		$1.71M Buy
15,109
+539
+4% +$61.5K 0.02% 257
2021
Q2 		$1.51M Buy
14,570
+9,019
+162% +$850K 0.02% 257
2021
Q1 		$465K Buy
5,551
+2,665
+92% +$225K 0.01% 504
2020
Q4 		$263K Sell
2,886
-5,823
-67% -$483K ﹤0.01% 602
2020
Q3 		$695K Buy
8,709
+196
+2% +$15.3K 0.01% 303
2020
Q2 		$588K Buy
8,513
+2,513
+42% +$179K 0.01% 311
2020
Q1 		$377K Buy
6,000
+798
+15% +$57.5K 0.01% 341
2019
Q4 		$405K Sell
5,202
-543
-9% -$42.4K 0.01% 347
2019
Q3 		$421K Buy
+5,745
New +$404K 0.01% 299
2019
Q2 		– Sell
-7,836
Closed -$500K – 852
2019
Q1 		$500K Buy
+7,836
New +$447K 0.02% 189

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Cresset Asset Management's EW Position: Q2 2026 in Review

Cresset Asset Management reduced its Edwards Lifesciences (EW) stake by 11% in Q2 2026, selling an estimated $96.2K and leaving 9,296 shares worth $841K. The position accounts for ﹤0.01% of the portfolio, ranked #976.

Cresset Asset Management first reported a position in EW in Q1 2019 and has held it in 29 quarters since. The position peaked at $4.29M in Q2 2024. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Cresset Asset Management held 9,296 shares of Edwards Lifesciences worth $841K as of Q2 2026.
  • Cresset Asset Management sold 1,148 Edwards Lifesciences shares in Q2 2026, an estimated $96.2K.
  • Edwards Lifesciences made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #976 holding.
  • Cresset Asset Management first reported a position in Edwards Lifesciences in Q1 2019 and has held it in 29 quarters since.
  • Cresset Asset Management's Edwards Lifesciences position peaked at $4.29M in Q2 2024.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.